NCT Number: NCT00147576
Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.
Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866,087 in alcohol dependent subjects compared to placebo.
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Pfizer Investigational Site, Cerritos, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subject meets the DSM-IV criterion for current alcohol dependence.
- Subject is currently not engaged in, and does not want, treatment for alcohol related problems.
Exclusion criteria
- Subject meets criteria for current DSM-IV diagnosis for any other psychoactive substance abuse or dependence disorder, excluding nicotine and caffeine.
- Specialized inpatient or outpatient alcoholism or other addiction treatment (except nicotine) within the past 12 months.
Treatment and study plan
Primary outcomes
-
The amount of alcohol consumed will be based on the total number of standardized drinks consumed during a two-hour laboratory-based self-administration procedure following 7 days of treatment with study medication.
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Official study title
Randomized, Placebo-Controlled Parallel Group Study Comparing Effect Of Three Doses Of CP-866,087 And Naltrexone On Acute Alcohol Consumption And Craving After Seven Days Of Treatment In Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking Treatment
Important dates
- Study start
- 2003
- Study completion
- 2004
- First posted
- Sep 7, 2005
- Registry last updated
- Oct 2, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU
NCT02723383
Aberrant Motor Behavior in Dementia, Alcohol Withdrawal Delirium
Angers, France
View Trial DetailsSleep Disturbance and Relapse in Individuals With Alcohol Dependence: An Exploratory Mixed Methods Study
NCT02181569
Alcohol-Related Disorders, Alcoholism
Bethesda, Maryland, United States
View Trial DetailsExploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot Study
NCT03152760
Alcohol-Related Disorders, Alcoholism
Bethesda, Maryland, United States
View Trial DetailsRepetitive Transcranial Magnetic Stimulation for Alcohol Use Disorder
NCT07755046
Alcohol Use Disorder (AUD), Alcohol-Related Disorders
Taichung, Taiwan
View Trial Details